Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 with gemcitabine and nab-paclitaxel in advanced pancreatic cancer
NL-OMON44952Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2014
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonidegib, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Dose-limiting toxicity and Maximum tolerated dose. Started Jan 2014; status: active, not recruiting.
02
Drugs
sonidegibgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON44952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44952.